BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Q, Zhong YJ, Yuan JP, Shao LH, Zhang J, Tang L, Liu SP, Hong YP, Firestone RA, Li Y. Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med 2013;11:192. [PMID: 23961994 DOI: 10.1186/1479-5876-11-192] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wei M, Guo X, Tu L, Zou Q, Li Q, Tang C, Chen B, Xu Y, Wu C. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Int J Nanomedicine 2015;10:5123-37. [PMID: 26316745 DOI: 10.2147/IJN.S87011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
2 Song K, Wang Z, Liu X, Zhang G, Wang X, Ouyang D, Guo M, Chen L. A novel dual sensitive polymer-gambogic acid conjugate: synthesis, characterization, and in vitro evaluation. Nanotechnology 2019;30:505701. [PMID: 31480032 DOI: 10.1088/1361-6528/ab40ee] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang J, Yuan JP, Wang Q, Shao LH, Liu SP, Firestone RA, Hong YP, Li JG, Xin YC, Li Y. Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer. Oncotarget 2018;9:1957-68. [PMID: 29416744 DOI: 10.18632/oncotarget.23319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 2015;15:712-29. [PMID: 26597527 DOI: 10.1038/nrc4027] [Cited by in Crossref: 297] [Cited by in F6Publishing: 281] [Article Influence: 59.4] [Reference Citation Analysis]
5 Mitra AK, Agrahari V, Mandal A, Cholkar K, Natarajan C, Shah S, Joseph M, Trinh HM, Vaishya R, Yang X, Hao Y, Khurana V, Pal D. Novel delivery approaches for cancer therapeutics. J Control Release 2015;219:248-68. [PMID: 26456750 DOI: 10.1016/j.jconrel.2015.09.067] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 12.0] [Reference Citation Analysis]
6 Li J, Zhang B, Yue C, Wu J, Zhao L, Sun D, Wang R. Strategies to release doxorubicin from doxorubicin delivery vehicles. Journal of Drug Targeting 2018;26:9-26. [DOI: 10.1080/1061186x.2017.1363209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Liu Y, Luo Y, Li X, Zheng W, Chen T. Rational Design of Selenadiazole Derivatives to Antagonize Hyperglycemia-Induced Drug Resistance in Cancer Cells. Chem Asian J 2015;10:642-52. [DOI: 10.1002/asia.201403409] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
8 Moradzadeh Khiavi M, Rostami A, Hamishekar H, Mesgari Abassi M, Aghbali A, Salehi R, Abdollahi B, Fotoohi S, Sina M. Therapeutic Efficacy of Orally Delivered Doxorubicin Nanoparticles in Rat Tongue Cancer Induced by 4-Nitroquinoline 1-Oxide. Adv Pharm Bull 2015;5:209-16. [PMID: 26236659 DOI: 10.15171/apb.2015.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang X, Li C, Zheng H, Song H, Li L, Xiong F, Yang J, Qiu T. Glutathione-dependent micelles based on carboxymethyl chitosan for delivery of doxorubicin. J Biomater Sci Polym Ed 2016;27:1824-40. [PMID: 27707353 DOI: 10.1080/09205063.2016.1238128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Karnthaler-Benbakka C, Koblmüller B, Mathuber M, Holste K, Berger W, Heffeter P, Kowol CR, Keppler BK. Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. Chem Biodivers 2019;16:e1800520. [PMID: 30566287 DOI: 10.1002/cbdv.201800520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Zhang ZT, Huang-Fu MY, Xu WH, Han M. Stimulus-responsive nanoscale delivery systems triggered by the enzymes in the tumor microenvironment. Eur J Pharm Biopharm 2019;137:122-30. [PMID: 30776412 DOI: 10.1016/j.ejpb.2019.02.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
12 Karali KK, Sygellou L, Stalikas CD. Highly fluorescent N-doped carbon nanodots as an effective multi-probe quenching system for the determination of nitrite, nitrate and ferric ions in food matrices. Talanta 2018;189:480-8. [DOI: 10.1016/j.talanta.2018.07.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 9.3] [Reference Citation Analysis]
13 Ruiz-Blázquez P, Pistorio V, Fernández-Fernández M, Moles A. The multifaceted role of cathepsins in liver disease. J Hepatol 2021:S0168-8278(21)01880-8. [PMID: 34242696 DOI: 10.1016/j.jhep.2021.06.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Di Giacomo S, Briz O, Monte MJ, Sanchez-Vicente L, Abete L, Lozano E, Mazzanti G, Di Sotto A, Marin JJG. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Arch Toxicol 2019;93:623-34. [PMID: 30659321 DOI: 10.1007/s00204-019-02395-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
15 Vizovišek M, Fonović M, Turk B. Cysteine cathepsins in extracellular matrix remodeling: Extracellular matrix degradation and beyond. Matrix Biology 2019;75-76:141-59. [DOI: 10.1016/j.matbio.2018.01.024] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 24.5] [Reference Citation Analysis]
16 Zhang J, He L, Geng X, Firestone RA, Hong Y, Li Y. Anti-cancer effects of novel doxorubicin prodrug PDOX in MCF-7 breast cancer cells. J Huazhong Univ Sci Technol [Med Sci ] 2014;34:521-8. [DOI: 10.1007/s11596-014-1309-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Maniganda S, Sankar V, Nair JB, Raghu KG, Maiti KK. A lysosome-targeted drug delivery system based on sorbitol backbone towards efficient cancer therapy. Org Biomol Chem 2014;12:6564-9. [PMID: 25062087 DOI: 10.1039/c4ob01153h] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
18 Das M, Solanki A, Joshi A, Devkar R, Seshadri S, Thakore S. β-cyclodextrin based dual-responsive multifunctional nanotheranostics for cancer cell targeting and dual drug delivery. Carbohydrate Polymers 2019;206:694-705. [DOI: 10.1016/j.carbpol.2018.11.049] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 15.5] [Reference Citation Analysis]
19 Vandooren J, Opdenakker G, Loadman PM, Edwards DR. Proteases in cancer drug delivery. Adv Drug Deliv Rev 2016;97:144-55. [PMID: 26756735 DOI: 10.1016/j.addr.2015.12.020] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 13.4] [Reference Citation Analysis]
20 Khare T, Khare S, Ibdah JA. Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol 2017; 9(1): 1-3 [PMID: 28144394 DOI: 10.4251/wjgo.v9.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Aggarwal N, Sloane BF. Cathepsin B: multiple roles in cancer. Proteomics Clin Appl. 2014;8:427-437. [PMID: 24677670 DOI: 10.1002/prca.201300105] [Cited by in Crossref: 159] [Cited by in F6Publishing: 150] [Article Influence: 22.7] [Reference Citation Analysis]
22 Yang J, Pei H, Luo H, Fu A, Yang H, Hu J, Zhao C, Chai L, Chen X, Shao X, Wang C, Wu W, Wan L, Ye H, Qiu Q, Peng A, Wei Y, Yang L, Chen L. Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways. Oncotarget 2017;8:915-32. [PMID: 27906672 DOI: 10.18632/oncotarget.13687] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
23 Yap ML, McFadyen JD, Wang X, Ziegler M, Chen YC, Willcox A, Nowell CJ, Scott AM, Sloan EK, Hogarth PM, Pietersz GA, Peter K. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics 2019;9:1154-69. [PMID: 30867822 DOI: 10.7150/thno.29146] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]